Pfizer has received a positive opinion from the European Medicines Agency (EMA) for its biosimilar rival to Herceptin (trastuzumab), after the agency’s committee for human medicinal products (CHMP) recommended granting a marketing authorisation for the firm’s Trazimera 150mg powder for concentrate for solution for infusion.
Pfizer has received a positive opinion from the European Medicines Agency (EMA) for its biosimilar rival to Herceptin (trastuzumab), after the agency’s committee for human medicinal products (CHMP) recommended granting a marketing authorisation for the firm’s Trazimera 150mg powder for concentrate for solution for infusion.
Noting that Trazimera was Pfizer’s fourth biosimilar and first oncology biosimilar to receive a positive CHMP opinion, the firm said...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
